B. Riley noted that Altimmune provided several pipeline updates along with reporting Q4 results, notably pertaining to pemvidutide execution through mid-stage clinical development. The Phase 2 MOMENTUM non-diabetes obesity study remains on track to report 160-subject 24-week interim analysis in the second half of March and final 48-week readout in Q4 and a new Phase 2 biopsy-proven NASH study is guided for mid-2023 initiation, said the analyst, noting in regards to the latter that the firm is "encouraged by the pace of execution to capitalize on the best-in-indication liver fat reduction" noted in the company’s recently concluded Phase Ib NAFLD study. B. Riley reiterates a Buy rating and $26 price target on Altimmune shares.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALT:
- Altimmune reports Q4 EPS (43c), consensus (50c)
- Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
- Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
- 3 Stocks to Buy Today, 2/14/2023, According to Top Analysts
- JMPS Securities biotech analysts hold an analyst/industry conference call